No Data
Hepalink Partners With Yongtai for U.S. Gabapentin Market
HEPALINK (09989.HK) signed a distribution agreement with Yongtai Pharmaceutical.
On January 2, Gelonghui reported that HEPALINK (09989.HK) announced that it had signed a distribution agreement with Zhejiang Yongtai Pharmaceutical Co., Ltd. ("Yongtai Pharmaceutical") on December 31, 2024, under which Yongtai Pharmaceutical granted the company the license to commercialize Gabapentin capsules ("symbol pharmaceutical") throughout the USA. According to the agreement, the company will purchase the symbol pharmaceutical from Yongtai Pharmaceutical at an agreed price and will be responsible for the commercialization of the symbol pharmaceutical in the USA. Aside from the supply price for the symbol pharmaceutical explicitly stated in the agreement, the company is not required to pay any additional amounts to Yongtai Pharmaceutical.
Express News | Shenzhen Hepalink Pharmaceutical - Yongtai Pharmaceutical to Grant Co License to Commercialize Gabapentin Capsules in US
Express News | Shenzhen Hepalink Pharmaceutical Group Co Ltd - Entering Into Distribution Agreement With Yongtai Pharmaceutical
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) Stocks Pounded By 35% But Not Lagging Market On Growth Or PricingSee the daily top gainer.
